Table 1. Patient characteristics by invasive mediastinal nodal staging status.
| Invasive mediastinal nodal staging | |||
|---|---|---|---|
| No (N=79) | Yes (N=79) | P value | |
| Median age (range) | 71 [46–87] | 77 [49–90] | 0.31 |
| Gender | 0.50 | ||
| Male | 39 (49%) | 40 (51%) | |
| Female | 40 (51%) | 39 (49%) | |
| Smoking history (pack years) | 0.25 | ||
| Median (IQR) | 62 [43.5–80] | 50 [40–75] | |
| Prior lung cancer | 0.85 | ||
| Yes | 20 (25%) | 18 (23%) | |
| No | 59 (75%) | 61 (77%) | |
| ECOG PS | 0.31 | ||
| 0 | 34 (43%) | 25 (32%) | |
| 1 | 35 (45%) | 46 (59%) | |
| 2 | 9 (12%) | 7 (9%) | |
| Missing | 1 | 1 | |
| Tumor lobe (primary) | 0.29 | ||
| RUL | 32 (40%) | 21 (27%) | |
| RML | 2 (2%) | 5 (6%) | |
| RLL | 14 (18%) | 15 (19%) | |
| LUL | 25 (30%) | 27 (34%) | |
| LLL | 6 (8%) | 11 (14%) | |
| Tumor histology (primary) | 0.28 | ||
| Adenocarcinoma | 28 (36%) | 26 (33%) | |
| Squamous cell carcinoma | 27 (34%) | 28 (36%) | |
| Other/non-diagnostic | 24 (30%) | 25 (31%) | |
| Tumor location (primary) | <0.0001 | ||
| Central | 10 (13%) | 32 (41%) | |
| Peripheral | 69 (87%) | 47 (59%) | |
| Clinical T-stage | 0.99 | ||
| T1 | 71 (82%) | 72 (78%) | |
| T2 | 15 (17%) | 16 (18%) | |
| Other | 1 (1%) | 4 (4%) | |
| Median tumor size (IQR) | 1.8 (1.4–2.8) | 1.9 (1.4–2.9) | 0.35 |
| Tumor appearance (primary) | 0.63 | ||
| Solid | 69 (87%) | 72 (91%) | |
| Ground glass opacity (GGO) | 7 (9%) | 4 (5%) | |
| Mixed (part solid, part GGO) | 3 (4%) | 3 (4%) | |
| PET/CT staging | 0.17 | ||
| Yes | 72 (91%) | 77 (97%) | |
| No | 7 (9%) | 2 (3%) | |
| Suspicious LN on PET/CT | 0.23 | ||
| Yes | 12 (16%) | 19 (25%) | |
| No | 61 (84%) | 58 (75%) | |
| Missing | 6 | 2 | |
| Median SBRT dose (range) | 4,800 [3,200–6,000] | 4,800 [3,200–6,000] | 0.55 |
IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group Performance Status; T-Stage, AJCC Clinical Criteria; GGO, ground-glass opacity; “Suspicious LN on PET/CT” represents the presence of a suspicious lymph node on PET during workup. SBRT, stereotactic body radiation therapy.